Moderna flu vaccine OK’d by FDA panel

In a pivotal move for global public health, a U.S. federal health advisory panel has unanimously endorsed Moderna mRNA-based flu vaccine, mFlusiva (mRNA-1010), for adults aged 50 and older. This groundbreaking recommendation by the Vaccines and Related Biological Products Advisory Committee (VRBPAC) on June 18, 2026, marks the imminent arrival of the first influenza shot leveraging the same messenger RNA technology that proved transformational during the COVID-19 pandemic. The decision brings a new era of vaccine innovation to the forefront of seasonal disease prevention, promising enhanced protection against a constantly evolving threat. The committee's 9-0 vote was supported by robust Phase 3 clinical trial data, which demonstrated approximately 26.6% relative vaccine efficacy against influenza-like illness compared to conventional vaccines in older adults. This endorsement represents a significant win for Moderna, which faced unusual regulatory headwinds, including an initial refusal-to-file letter from the FDA in early 2024 that was later reversed amid political scrutiny surrounding vaccine research and the influence of Health and Human Services Secretary Robert F. Kennedy Jr.. The mRNA platform's potential for faster updates and broader immune response against various flu strains could fundamentally reshape the vaccine landscape, offering a critical edge over traditional egg-based production methods. The FDA is now expected to issue its final approval decision by August 5, 2026, paving the way for mFlusiva potential rollout for the upcoming fall flu season. However, the path to widespread adoption is not without hurdles; an anticipated recommendation from the Advisory Committee on Immunization Practices (ACIP) is still critical for insurer coverage and comprehensive clinical guidance, with some reports citing ongoing 'ACIP turmoil' and legal disputes that could delay a smooth market entry. Should these challenges be navigated, Moderna mFlusiva could represent a significant step towards more effective and adaptable annual flu protection, intensifying competition with other players like Pfizer and BioNTech also developing mRNA flu vaccine.